Insider Selling: USANA Health Sciences (NYSE:USNA) Director Sells 1,058 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert Fuller sold 1,058 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $17.00, for a total value of $17,986.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

USANA Health Sciences Stock Down 1.5%

USNA traded down $0.26 during trading hours on Friday, reaching $16.88. 201,219 shares of the company’s stock traded hands, compared to its average volume of 156,058. The firm has a 50-day moving average price of $20.29 and a 200 day moving average price of $21.88. USANA Health Sciences, Inc. has a 52-week low of $16.72 and a 52-week high of $38.32. The firm has a market capitalization of $311.66 million, a PE ratio of 30.70, a PEG ratio of 0.71 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The business had revenue of $226.20 million for the quarter, compared to analyst estimates of $225.96 million. Equities analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors have recently made changes to their positions in the company. National Bank of Canada FI raised its holdings in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares in the last quarter. Parallel Advisors LLC increased its position in USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after purchasing an additional 3,589 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after purchasing an additional 1,327 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in shares of USANA Health Sciences in the 3rd quarter valued at about $120,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Zacks Research upgraded shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, USANA Health Sciences currently has an average rating of “Reduce”.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.